newsfilter
← Latest News
GlobeNewswire·

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell